IO Biotech

Yahoo Finance • 2 days ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster presentation will share final data from Phase 2 ba... Full story

Yahoo Finance • 21 days ago

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior... Full story

Yahoo Finance • 30 days ago

H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14

IO Biotech, Inc. (NASDAQ:IOBT) is one of the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 15, H.C. Wainwright reiterated a Buy rating on IO Biotech, Inc. (NASDAQ:IOBT), keeping its price target at $14. Emily Bod... Full story

Yahoo Finance • last month

In today's session, these stocks are experiencing unusual volume.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT VMAR [https://www.chartmill.com/stock/quote/VMAR/profile]... Full story

Yahoo Finance • last month

Top movers in Friday's session

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE CO... Full story

Yahoo Finance • last month

These stocks have an unusual volume in today's session

Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -29.04% 56.82M s... Full story

Yahoo Finance • last month

Top movers in Tuesday's session

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • last month

These stocks are moving in today's after hours session

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT ANY [https://www.chartmill.com/stock/qu... Full story

Yahoo Finance • last month

Which stocks are experiencing notable movement on Monday?

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 77.82% Positive ma... Full story

Yahoo Finance • last month

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 87.56% With a 87.56% surge... Full story

Yahoo Finance • last month

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Wang & Lee Group Inc. 319,475,864 0.069 0.0559 0.0592 +0.0134 Entero The... Full story

Yahoo Finance • last month

Monday's pre-market session: top gainers and losers

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT E... Full story

Yahoo Finance • last month

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

IO Biotech Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-... Full story

Yahoo Finance • 2 months ago

IO Biotech files to sell 4.22M shares of common stock for holders

* IO Biotech (NASDAQ:IOBT [https://seekingalpha.com/symbol/IOBT]) filed a prospectus for the offer and sale of 4.22M shares of common stock by the selling stockholders.  * This prospectus is not an offer to sell these securities.  *... Full story

Yahoo Finance • 4 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, t... Full story

Yahoo Finance • 4 months ago

IO Biotech price target raised to $14 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses for the target increase. The analyst sa... Full story

Yahoo Finance • 4 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data presented at recent congresses reinforc... Full story

Yahoo Finance • 5 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific... Full story

Yahoo Finance • 6 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical d... Full story

Yahoo Finance • 7 months ago

IO Biotech Reports 2024 Business Highlights

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 p... Full story